Impact BioMedical, Inc. (IBO)vsJohnson & Johnson (JNJ)
IBO
Impact BioMedical, Inc.
$0.66
-2.59%
HEALTHCARE · Cap: $71.16M
JNJ
Johnson & Johnson
$229.85
-1.16%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 301131138% more annual revenue ($96.36B vs $32,000). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
IBO
Avoid15
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IBO.
Margin of Safety
-41.6%
Fair Value
$160.43
Current Price
$229.85
$69.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : IBO
The strongest argument for IBO centers on Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : IBO
The primary concerns for IBO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IBO profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 15/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is a forward-thinking biotechnology firm dedicated to the development of pioneering therapeutics and technologies that tackle pressing healthcare issues. The company employs cutting-edge research and development methodologies to enhance patient health outcomes and elevate quality of life. With a strong intellectual property portfolio and a focus on scientific excellence, Impact BioMedical is strategically positioned for significant growth in the dynamic healthcare landscape. Its diverse product pipeline and strategic partnerships present promising opportunities for institutional investors seeking to invest in the transformative advancements of the biopharmaceutical sector.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?